Adaptive Biotechnologies (ADPT) Invested Capital: 2018-2025
Historic Invested Capital for Adaptive Biotechnologies (ADPT) over the last 7 years, with Sep 2025 value amounting to $206.9 million.
- Adaptive Biotechnologies' Invested Capital fell 7.56% to $206.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.9 million, marking a year-over-year decrease of 7.56%. This contributed to the annual value of $203.6 million for FY2024, which is 33.99% down from last year.
- Adaptive Biotechnologies' Invested Capital amounted to $206.9 million in Q3 2025, which was up 13.17% from $182.8 million recorded in Q2 2025.
- In the past 5 years, Adaptive Biotechnologies' Invested Capital ranged from a high of $725.7 million in Q1 2021 and a low of $182.8 million during Q2 2025.
- Over the past 3 years, Adaptive Biotechnologies' median Invested Capital value was $241.6 million (recorded in 2024), while the average stood at $274.5 million.
- Per our database at Business Quant, Adaptive Biotechnologies' Invested Capital spiked by 31.57% in 2021 and then tumbled by 38.99% in 2024.
- Quarterly analysis of 5 years shows Adaptive Biotechnologies' Invested Capital stood at $604.1 million in 2021, then decreased by 23.16% to $464.2 million in 2022, then slumped by 33.56% to $308.4 million in 2023, then tumbled by 33.99% to $203.6 million in 2024, then fell by 7.56% to $206.9 million in 2025.
- Its Invested Capital stands at $206.9 million for Q3 2025, versus $182.8 million for Q2 2025 and $192.4 million for Q1 2025.